Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Hematologic Malignancy Reports
Published in: Current Hematologic Malignancy Reports 2/2019

01-04-2019 | Acute Lymphoblastic Leukemia | Acute Lymphocytic Leukemias (K Ballen and M Keng, Section Editors)

Relapsed T Cell ALL: Current Approaches and New Directions

Authors: Christine M. McMahon, Selina M. Luger

Published in: Current Hematologic Malignancy Reports | Issue 2/2019

Login to get access

Abstract

Purpose of Review

Patients with relapsed T cell acute lymphoblastic leukemia (T-ALL) have limited therapeutic options and a poor prognosis. Although a variety of salvage chemotherapy regimens may be used, response rates are unsatisfactory. This article summarizes current approaches and promising emerging strategies for the treatment of relapsed T-ALL.

Recent Findings

Although nelarabine is the only agent approved specifically for T-ALL, recent studies have identified a variety of genetic alterations and signaling pathways that are critical in its pathogenesis. Based on these findings, a number of small-molecule inhibitors and other targeted therapies are being studied for relapsed T-ALL, including gamma-secretase inhibitors, BCL-2 inhibitors, cyclin-dependent kinase inhibitors, and mTOR inhibitors. In addition, pre-clinical studies of chimeric antigen receptor T cells targeting CD5 and CD7 as well as the monoclonal antibody daratumumab have shown promising results for T-ALL.

Summary

Relapsed T-ALL currently remains challenging to treat, but recent pre-clinical studies of targeted and immunotherapeutic agents have shown encouraging results. A number of clinical trials investigating these approaches for T-ALL are currently underway.
Literature
1.
Dores GM, Devesa SS, Curtis RE, Linet MS, Morton LM, Dores GM, et al. Acute leukemia incidence and patient survival among children and adults in the United States, 2001–2007. Blood. 2011;119:34–43.CrossRefPubMed
2.
Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the Children’s Oncology Group. J Clin Oncol. 2012;(30):1663–9.
3.
Winter SS, Dunsmore KP, Devidas M, Wood BL, Esiashvili N, Chen Z, et al. Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the Children’s Oncology Group AALL0434 methotrexate randomization. J Clin Oncol. 2018;36:2926–34.CrossRefPubMedPubMedCentral
4.
Marks DI, Paietta EM, Moorman AV, Richards SM, Buck G, Dewald G, et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood. 2009;114:5136–45.CrossRefPubMedPubMedCentral
5.
Stock W, Luger SM, Advani AS, Geyer S, Harvey RC, Mullighan CG, et al. Favorable outcomes for older adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL): early results of U.S. Intergroup Trial C10403 [Abstract]. Blood. 2014;124:796.
6.
Marks DI, Rowntree C. Management of adults with T-cell lymphoblastic leukemia. Blood. 2017;129:1134–42.CrossRefPubMed
7.
•• Beldjord K, Chevret S, Asnafi V, Boulland M-L, Leguay T, Thomas X, et al. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. 2016;123:3739–50 Beldjord et al. analyzed MRD levels in patients with T-ALL and B cell precursor ALL following induction chemotherapy and demonstrated that post-induction MRD levels ≥ 10 −4 predicted an increased risk of relapse.
8.
Schrappe M, Valsecchi MG, Bartram CR, Schrauder A, Panzer-Grümayer R, Möricke A, et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood. 2011;118:2077–84.CrossRefPubMed
9.
Brüggemann M, Raff T, Flohr T, Go N, Nakao M, Droese J, et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood. 2006;107:1116–23.CrossRefPubMed
10.
• Möricke A, Zimmermann M, Valsecchi MG, Stanulla M, Biondi A, Mann G, et al. Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. Blood. 2016;127:2101–12 This study which randomized pediatric patients with ALL to receive dexamethasone vs. prednisone during induction therapy demonstrated a decreased risk of relapse but a higher rate of induction-related deaths in the group that received dexamethasone. CrossRefPubMed
11.
Asselin BL, Devidas M, Wang C, Pullen J, Borowitz MJ, Hutchison R, et al. Effectiveness of high dose methotrexate in T-cell lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a randomized study by the Children’s Oncology Group (POG 9404). Blood. 2011;118:874–84.CrossRefPubMedPubMedCentral
12.
Wetzler M, Sanford BL, Kurtzberg J, DeOliveira D, Frankel SR, Powell BL, et al. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B study 9511. Blood. 2007;109:4164–7.CrossRefPubMedPubMedCentral
13.
Gökbuget N, Baumann A, Beck J, Brueggemann M, Diedrich H, Huettmann A, et al. PEG-asparaginase intensification in adult acute lymphoblastic leukemia (ALL): significant improvement of outcome with moderate increase of liver toxicity In the German Multicenter Study Group for Adult ALL (GMALL) Study 07/2003 [Abstract]. Blood. 2010;116:494.
14.
DeAngelo DJ, Stevenson KE, Dahlberg SE, Silverman LB, Couban S, Supko JG, et al. Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2015;29:526–34.CrossRefPubMed
15.
Hoelzer D, Thiel E, Arnold R, Beck J, Beelen DW, Bornhäuser M, et al. Successful subtype oriented treatment strategies in adult T-ALL: results of 744 patients treated in three consecutive GMALL studies [Abstract]. Blood. 2009;114:324.
16.
Dunsmore KP, Devidas M, Linda SB, Borowitz MJ, Winick N, Hunger SP, et al. Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children’s Oncology Group. J Clin Oncol. 2012;30:2753–9.CrossRefPubMedPubMedCentral
17.
Jain P, Kantarjian H, Ravandi F, Thomas D, O’Brien S, Kadia T, et al. The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience. Leukemia. 2014;28:973–5.CrossRefPubMed
18.
Abaza Y, M. Kantarjian H, Faderl S, Jabbour E, Jain N, Thomas D, et al. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. Am J Hematol. 2018;93:91–9.CrossRefPubMed
19.
• Dunsmore KP, Winter S, Devidas M, Wood BL, Esiashvili N, Eisenberg N, et al. COG AALL0434: a randomized trial testing nelarabine in newly diagnosed T-cell malignancy [Abstract]. J Clin Oncol. 2018;36:10500 The initial results of the large COG AALL0434 study which randomized pediatric and young adult patients with newly diagnosed T-ALL to receive or not receive nelarabine demonstrated improved 4-year DFS in the patients that received nelarabine. CrossRef
20.
Arber DA, Orazi A, Hasserjian R, Borowitz MJ, Le Beau MM, Bloomfield CD, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–406.CrossRefPubMed
21.
Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 2012;481:157–63.CrossRefPubMedPubMedCentral
22.
Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 2009;10:147–56.CrossRefPubMedPubMedCentral
23.
Patrick K, Wade R, Goulden N, Mitchell C, Moorman AV, Rowntree C, et al. Outcome for children and young people with early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. Br J Haematol. 2014;166:421–4.CrossRefPubMed
24.
Wood BL, Winter SS, Dunsmore KP, Devidas M, Chen S, Asselin B, et al. T-lymphoblastic leukemia (T-ALL) shows excellent outcome, lack of significance of the ETP immunophenotype, and validation of the prognostic value of end-induction MRD in COG study AALL0434 [abstract]. Blood 2014;124:1–1.
25.
Reismüller B, Attarbaschi A, Peters C, Dworzak MN, Pötschger U, Urban C, et al. Long-term outcome of initially homogenously treated and relapsed childhood acute lymphoblastic leukaemia in Austria - a population-based report of the Austrian Berlin-Frankfurt-Münster (BFM) Study Group. Br J Haematol. 2009;144:559–70.CrossRefPubMed
26.
• Desjonquères A, Chevallier P, Thomas X, Huguet F, Leguay T, Bernard M, et al. Acute lymphoblastic leukemia relapsing after first-line pediatric-inspired therapy: a retrospective GRAALL study. Blood Cancer J. 2016;6:e504 This large retrospective analysis of adults with relapsed Ph-ALL demonstrated that there is no specific standard of care regimen for relapsed T-ALL. CrossRefPubMedPubMedCentral
27.
Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007;109:944–50.CrossRefPubMed
28.
Cohen A, Lee JWW, Gelfand EW. Selective toxicity of deoxyguanosine and arabinosyl guanine for T-leukemic cells. Blood. 1983;61:660–7.PubMed
29.
Kisor DF, Plunkett W, Kurtzberg J, Mitchell B, Hodge JP, Ernst T, et al. Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. J Clin Oncol. 2000;18:995–1003.CrossRefPubMed
30.
Shewach DS, Daddona PE, Ashcroft E, Mitchell BS. Metabolism and selective cytotoxicity of 9-B-D-arabinofuranosyiguanine in human lymphoblasts. Cancer Res. 1985;45:1008–14.PubMed
31.
Lambe CU, Averett DR, Paff MT, Reardon JE, Wilson JG, Krenitsky TA. 2-Amino-6-methoxypurine arabinoside: an agent for T-cell malignancies. Cancer Res. 1995;100:3352–6.
32.
Kurtzberg J, Ernst TJ, Keating MJ, Gandhi V, Hodge JP, Kisor DF, et al. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol. 2005;23:3396–403.CrossRefPubMed
33.
Cohen MH, Johnson JR, Justice R, Pazdur R. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma. Oncologist. 2008;13:709–14.CrossRefPubMed
34.
Berg SL, Blaney SM, Devidas M, Lampkin TA, Murgo A, Bernstein M, et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children’s Oncology Group. J Clin Oncol. 2005;23:3376–82.CrossRefPubMed
35.
DeAngelo DJ, Yu D, Johnson JL, Coutre SE, Stone RM, Stopeck AT, et al. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood. 2007;109:5136–42.CrossRefPubMedPubMedCentral
36.
Gökbuget N, Basara N, Baurmann H, Beck J, Brüggemann M, Diedrich H, et al. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. Blood. 2011;118:3504–11.CrossRefPubMed
37.
Commander LA, Seif AE, Insogna IG, Rheingold SR. Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma. Br J Haematol. 2010;150:345–51.CrossRefPubMed
38.
Luskin MR, Ganetsky A, Landsburg DJ, Loren AW, Porter DL, Nasta SD, et al. Nelarabine, cyclosphosphamide and etoposide for adults with relapsed T-cell acute lymphoblastic leukaemia and lymphoma. Br J Haematol. 2016;174:332–4.CrossRefPubMed
39.
Silverman JA, Deitcher SR. Marqibo®(vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine. Cancer Chemother Pharmacol. 2013;71:555–64.CrossRefPubMed
40.
Webb MS, Harasym TO, Masin D, Bally MB, Mayer LD. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br J Cancer. 1995;72:896–904.CrossRefPubMedPubMedCentral
41.
Webb MS, Logan P, Kanter PM, St.-Onge G, Gelmon K, Harasym T, et al. Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer. Cancer Chemother Pharmacol. 1998;42:461–70.CrossRefPubMed
42.
Krishna R, Webb MS, St MLD. Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. J Pharmacol Exp Ther. 2001;298:1206–12.PubMed
43.
O’Brien S, Schiller G, Lister J, Damon L, Goldberg S, Aulitzky W, et al. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. J Clin Oncol. 2013;31:676–83.CrossRefPubMed
44.
Shah NN, Merchant MS, Cole DE, Jayaprakash N, Bernstein D, Delbrook C, et al. Vincristine sulfate liposomes injection (VSLI, Marqibo): results from a phase I study in children, adolescents, and young adults with refractory solid tumors or leukemias. Pediatr Blood Cancer. 2016;63:997–1005.CrossRefPubMedPubMedCentral
45.
Belver L, Ferrando A. The genetics and mechanisms of T cell acute lymphoblastic leukaemia. Nat Rev Cancer. 2016;16:494–507.CrossRefPubMed
46.
Weng AP, Ferrando AA, Lee W, Morris JP, Silverman LB, Sanchez-Irizarry C, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004;306(80):269–71.CrossRefPubMed
47.
Sanchez-Martin M, Ferrando A. The NOTCH1-MYC highway toward T-cell acute lymphoblastic leukemia. Blood. 2017;129:1124–33.CrossRefPubMed
48.
Maillard I. Notch and human hematopoietic stem cells. Blood. 2015;123:1116–9.
49.
Paganin M, Ferrando A. Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia. Blood Rev. 2011;25:83–90.CrossRefPubMed
50.
•• Liu Y, Easton J, Shao Y, Maciaszek J, Wang Z, Wilkinson MR, et al. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat Genet. 2017;49:1211–8 This genetic and RNA expression study on samples collected from 264 children and young adults with T-ALL identified 106 driver mutations, 39 novel gene rearrangements, and 10 pathways commonly dysregulated in T-ALL, illustrating the tremendous genetic heterogeneity of T-ALL and revealing potentially targetable pathways. CrossRefPubMedPubMedCentral
51.
O’Neil J, Grim J, Strack P, Rao S, Tibbitts D, Winter C, et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to γ-secretase inhibitors. J Exp Med. 2007;204:1813–24.CrossRefPubMedPubMedCentral
52.
Real PJ, Tosello V, Palomero T, Castillo M, Hernando E, De Stanchina E, et al. γ-Secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med. 2009;15:50–8.CrossRefPubMed
53.
De Keersmaecker K, Lahortiga I, Mentens N, Folens C, Van Neste L, Bekaert S, et al. In vitro validation of γ-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia. Haematologica. 2008;93:533–42.CrossRefPubMed
54.
Samon JB, Castillo-Martin M, Hadler M, Ambesi-Impiobato A, Paietta E, Racevskis J, et al. Preclinical analysis of the gamma-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia. Mol Cancer Ther. 2012;11:1565–75.CrossRefPubMedPubMedCentral
55.
Gavai AV, Quesnelle C, Norris D, Han WC, Gill P, Shan W, et al. Discovery of clinical candidate BMS-906024: a potent pan-notch inhibitor for the treatment of leukemia and solid tumors. ACS Med Chem Lett. 2015;6:523–7.CrossRefPubMedPubMedCentral
56.
Deangelo DJ, Stone RM, Silverman LB, Stock W, Attar EC, Fearen I, et al. A phase I clinical trial of the Notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias [Abstract]. J Clin Oncol. 2006;24:6585.
57.
Zweidler-McKay PA, Deangelo DJ, Douer D, Dombret H, Ottmann OG, Vey N, et al. The safety and activity of BMS-906024, a gamma secretase inhibitor with anti-Notch activity, in patients with relapsed T-cell acute lymphoblastic leukemia: initial results of a phase 1 trial [Abstract]. Blood. 2014;124:968.
58.
Papayannidis C, DeAngelo DJ, Stock W, Huang B, Shaik MN, Cesari R, et al. A phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Blood Cancer J. 2015;5:e350–3.CrossRefPubMedPubMedCentral
59.
Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K, Ciofani M, et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med. 2007;13:1203–10.CrossRefPubMedPubMedCentral
60.
Knoechel B, Roderick JE, Williamson KE, Zhu J, Lohr JG, Cotton MJ, et al. An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. Nat Genet. 2014;46:364–70.CrossRefPubMedPubMedCentral
61.
• Sanchez-Martin M, Ambesi-Impiombato A, Qin Y, Herranz D, Bansal M, Girardi T, et al. Synergistic antileukemic therapies in NOTCH1 -induced T-ALL. Proc Natl Acad Sci. 2017;114:2006–11 This study identified several drugs that are synergistic with GSIs in the pre-clinical setting for the treatment of T-ALL. CrossRefPubMedPubMedCentral
62.
Pinnell N, Yan R, Cho HJ, Keeley T, Murai MJ, Liu Y, et al. The PIAS-like coactivator Zmiz1 is a direct and selective cofactor of Notch1 in T cell development and leukemia. Immunity. 2015;43:870–83.CrossRefPubMedPubMedCentral
63.
Roti G, Carlton A, Ross KN, Markstein M, Pajcini K, Su AH, et al. Complementary genomic screens identify SERCA as a therapeutic target in NOTCH1 mutated cancer. Cancer Cell. 2013;23:390–405.CrossRefPubMedPubMedCentral
64.
Roderick JE, Tesell J, Shultz LD, Brehm MA, Greiner DL, Harris MH, et al. c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells. Blood. 2014;123:1040–51.CrossRefPubMedPubMedCentral
65.
Moellering RE, Cornejo M, Davis TN, Del Bianco C, Aster JC, Blacklow SC, et al. Direct inhibition of the NOTCH transcription factor complex. Nature. 2009;462:182–8.CrossRefPubMedPubMedCentral
66.
Wu Y, Cain-Hom C, Choy L, Hagenbeek TJ, De Leon GP, Chen Y, et al. Therapeutic antibody targeting of individual Notch receptors. Nature. 2010;464:1052–7.CrossRefPubMed
67.
Agnusdei V, Minuzzo S, Frasson C, Grassi A, Axelrod F, Satyal S, et al. Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts. Leukemia. 2014;28:278–88.CrossRefPubMed
68.
Alcantara M, Tesio M, June CH, Houot R, T-cells CAR. CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells. Leukemia. 2018;32:2307–15.CrossRefPubMedPubMedCentral
69.
•• Mamonkin M, Rouce RH, Tashiro H, Brenner MK. A T-cell – directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood. 2015;126:983–93 Mamonkin et al. showed that CAR T cells targeting CD5 are effective against T-ALL cells in vitro and in vivo. CrossRefPubMedPubMedCentral
70.
•• Gomes-Silva D, Srinivasan M, Sharma S, Lee CM, Wagner DL, Davis TH, et al. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood. 2017;130:285–96 This important proof-of-concept study showed that gene editing to prevent the expression of CD7 in CAR Tcells that were engineered to target CD7 allowed for the efficacious targeting of T-ALL cells in vitro and in a mouse xenograft model with minimal fratricide. CrossRefPubMedPubMedCentral
71.
• Cooper ML, Choi J, Staser K, Ritchey JK, Devenport JM, Eckardt K, et al. An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies. Leukemia. 2018;32:1970–83 This study demonstrated efficacy of “off the shelf” CAR T cells targeting CD7 that lack both CD7 and T cell receptor alpha chain expression against T-ALL cells in vitro and in xenograft models. CrossRefPubMedPubMedCentral
72.
Png YT, Vinanica N, Kamiya T, Shimasaki N, Coustan-Smith E, Campana D. Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies. Blood Adv. 2017;1:2348–60.CrossRefPubMedPubMedCentral
73.
•• Bride KL, Vincent TL, Im S-Y, Aplenc R, Barrett DM, Carroll WL, et al. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia (T-ALL). Blood. 2018;131:995–9 This study demonstrated that CD38 is expressed on the majority of T-ALL blasts and that daratumumab is effective in pre-clinical models of T-ALL, which provided the rationale for an ongoing trial of daratumumab for relapsed T-ALL. CrossRefPubMedPubMedCentral
74.
Zheng W, Medeiros LJ, Young KH, Goswami M, Powers L, Kantarjian HH, et al. CD30 expression in acute lymphoblastic leukemia as assessed by flow cytometry analysis. Leuk Lymphoma. 2014;55:624–7.CrossRefPubMed
75.
Passaro D, Irigoyen M, Catherinet C, Gachet S, Da Costa De Jesus C, Lasgi C, et al. CXCR4 is required for leukemia-initiating cell activity in T cell acute lymphoblastic leukemia. Cancer Cell. 2015;27:769–79.CrossRefPubMed
76.
Chonghaile TN, Roderick JE, Glenfield C, Ryan J, Sallan SE, Silverman LB, et al. Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discov. 2014;4:1074–87.CrossRefPubMedPubMedCentral
77.
• Peirs S, Matthijssens F, Goossens S, Van De Walle I, Ruggero K, De Bock CE, et al. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood. 2015;124:3738–48 This study showed that a subset of T-ALLs, particularly those with an immature immunophenotype, are sensitive to BCL-2 inhibition in vitro and in vivo and provided the pre-clinical rationale for several ongoing studies of venetoclax for relapsed and/or refractory ALL. CrossRef
78.
Sawai CM, Freund J, Oh P, Ndiaye-Lobry D, Bretz JC, Strikoudis A, et al. Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia. Cancer Cell Elsevier Inc.; 2012:22:452–65.
79.
Jena N, Sheng J, Hu JK, Li W, Zhou W, Lee G, et al. CDK6-mediated repression of CD25 is required for induction and maintenance of Notch1-induced T-cell acute lymphoblastic leukemia. Leukemia. 2016;30:1033–43.CrossRefPubMed
80.
Pikman Y, Alexe G, Roti G, Conway AS, Furman A, Lee ES, et al. Synergistic drug combinations with a CDK4/6 inhibitor in T-cell acute lymphoblastic leukemia. Clin Cancer Res. 2017;23:1012–24.CrossRefPubMed
81.
Palomero T, Dominguez M, Ferrando AA. The role of the PTEN/AKT pathway in NOTCH1-induced leukemia. Cell Cycle. 2008;7:965–70.CrossRefPubMed
82.
Gutierrez A, Sanda T, Grebliunaite R, Carracedo A, Salmena L, Ahn Y, et al. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood. 2009;114:647–50.CrossRefPubMedPubMedCentral
83.
Piovan E, Yu J, Tosello V, Herranz D, Ambesi-Impiombato A, DaSilva AC, et al. Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia. Cancer Cell. 2013;24:766–76.CrossRefPubMed
84.
Wei G, Twomey D, Lamb J, Schlis K, Agarwal J, Stam RW, et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell. 2006;10:331–42.CrossRefPubMed
85.
Subramaniam PS, Whye DW, Efimenko E, Chen J, Tosello V, De Keersmaecker K, et al. Targeting nonclassical oncogenes for therapy in T-ALL. Cancer Cell. 2012;21:459–72.CrossRefPubMed
86.
Efimenko E, Davé UP, Lebedeva IV, Shen Y, Sanchez-Quintero MJ, Diolaiti D, et al. PI3Kγ/δ and NOTCH1 cross-regulate pathways that define the T-cell acute lymphoblastic leukemia disease signature. Mol Cancer Ther. 2017;16:2069–82.CrossRefPubMedPubMedCentral
87.
Graux C, Cools J, Melotte C, Quentmeier H, Ferrando A, Levine R, et al. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet. 2004;36:1084–9.CrossRefPubMed
88.
Burmeister T, Gökbuget N, Reinhardt R, Rieder H, Hoelzer D, Schwartz S. NUP214-ABL1 in adult T-ALL: the GMALL study group experience. Blood. 2006;108:3556–9.CrossRefPubMed
89.
Quintás-Cardama A, Tong W, Manshouri T, Vega F, Lennon PA, Cools J, et al. Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies. Leukemia. 2008;22:1117–24.CrossRefPubMed
90.
Deenik W, Beverloo HB, van der Poel-van de Luytgaarde SCPAM, Wattel MM, van Esser JWJ, Valk PJM, et al. Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia. Leukemia. 2009;23:627–9.CrossRefPubMed
91.
Clarke S, O’Reilly J, Romeo G, Cooney J. NUP214-ABL1 positive T-cell acute lymphoblastic leukemia patient shows an initial favorable response to imatinib therapy post relapse. Leuk Res. 2011;35:131–3.CrossRef
Metadata
Title
Relapsed T Cell ALL: Current Approaches and New Directions
Authors
Christine M. McMahon
Selina M. Luger
Publication date
01-04-2019
Publisher
Springer US
Published in
Current Hematologic Malignancy Reports / Issue 2/2019
Print ISSN: 1558-8211
Electronic ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-019-00501-3

Other articles of this Issue 2/2019

Current Hematologic Malignancy Reports 2/2019 Go to the issue

Correction

Correction to: Autologous Haematopoietic Stem Cell Transplantation in Multiple Sclerosis: a Review of Current Literature and Future Directions for Transplant Haematologists and Oncologists

Stem Cell Transplantation (R Maziarz, Section Editor)

Autologous Haematopoietic Stem Cell Transplantation in Multiple Sclerosis: a Review of Current Literature and Future Directions for Transplant Haematologists and Oncologists

T-Cell and Other Lymphoproliferative Malignancies (J Zain, Section Editor)

Development and Significance of Mouse Models in Lymphoma Research

ReviewPaper

Recent Advances in Adult Acute Lymphoblastic Leukemia

Acute Lymphocytic Leukemias (K Ballen and M Keng, Section Editors)

Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoblastic Leukemia

Multiple Myeloma (P Kapoor, Section Editor)

Challenges and Strategies in the Management of Multiple Myeloma in the Elderly Population
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits